Power Of Proprietary Drug Names To Be Studied By US FDA
Executive Summary
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.
You may also be interested in...
Celebrity Takes Role In US FDA Study Of Rx Drug Endorsements
Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.
Epidiolex Almost Didn't Get Proprietary Name Because Of Confusion With OTC Pedia-Lax
US FDA's lead name reviewer laid out slew of reasons why the two names could be confused; her bosses agreed with the individual points, but felt that mitigation measures to avoid confusion were sufficient when considered holistically.
PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies
US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
